Business Daily from THE HINDU group of publications
Tuesday, May 13, 2008
ePaper | Mobile/PDA Version | Audio


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements
Aurobindo plan gets S African nod

Hyderabad, May 12.

Aurobindo Pharma Ltd has received approvals from the Medicines Control Council (MCC) to manufacture and market nine products in South Africa. These products are estimated to have a generic market size of ZAR 165 million in South African currency in the local market, the Hyderabad-based, pharma major has informed the BSE. With this, Aurobindo now has a total of 31 marketing authorisations approved by the council, the South African regulatory body. —

Our Bureau

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Nano rollout on schedule


Aurobindo plan gets S African nod
Kewal Kiran raises Rs 80.6 cr
Kirloskar Ferrous converts warrants
Graphite India to add 10,500 t at Durgapur plant
‘Phase-2 of Simhadri power plant to be completed by 2011’
Hero Electric to invest Rs 80 cr for expansion
Welcome to TN
Veeda Oncology close to buying US clinical research unit
Jindal, Antam form venture for nickel smelting, stainless steel unit
NTPC eyes majority stake in Indonesian coal blocks
Phillips Carbon doubles funds for Vietnam jt venture
Bajaj-Renault-Nissan to drive small car by 2011
Bajaj-Renault-Nissan takes up challenge of $2,500 car
Ranbaxy, Merck in pact for anti-infective drugs
Hind Zinc 32 model villages get ORG certification
CIL e-auction may dip during May-July
Mercator to invest Rs 4,000 cr
IIP numbers resurrect concerns for India Inc


Smartbuy



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line